Chronic kidney disease: issues and establishing programs and clinics for improved patient outcomes (Q35117574)

6 August 2017

1 reference

title

Chronic kidney disease: issues and establishing programs and clinics for improved patient outcomes (English)

1 reference

chronic renal insufficiency

6 August 2017

1 reference

1 reference

4

William M McClellan

1 reference

6 August 2017

Wendy L St Peter

1

1 reference

PubMed ID

12722025

6 August 2017

Anton C Schoolwerth

series ordinal

2

1 reference

PubMed ID

12722025

6 August 2017

Tracy McGowan

series ordinal

3

1 reference

6 August 2017

1 May 2003

1 reference

American Journal of Kidney Diseases

6 August 2017

1 reference

6 August 2017

41

1 reference

6 August 2017

5

1 reference

6 August 2017

903-924

1 reference

Chronic renal confusion: insufficiency, failure, dysfunction, or disease

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Morbidity and mortality of renal dialysis: an NIH consensus conference statement. Consensus Development Conference Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

The prognostic significance of proteinuria: the Framingham study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Biochemical parameters in chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Defining a renal anemia management period

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Quality of life in predialytic uremic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Quality of life and psychosocial relationships in patients with chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

rHuEPO treatment improves brain and cognitive function of anemic dialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

National Cooperative rHu Erythropoietin Study in patients with chronic renal failure--an interim report. The National Cooperative rHu Erythropoietin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

How should anaemia be managed in pre-dialysis patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Use of erythropoietin before the initiation of dialysis and its impact on mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Anemia treatment in the pre-ESRD period and associated mortality in elderly patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Morbidity and mortality in dialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

The role of phosphorus in the development of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Medical management of secondary hyperparathyroidism in uremia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Phosphate binders for control of phosphate retention in chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Hyperlipidemia in patients with chronic renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Blood pressure and end-stage renal disease in men

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Are drugs that block the renin-angiotensin system effective and safe in patients with renal insufficiency?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Renal disease and hypertension in non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Cardiovascular disease in chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Predictors of hospitalization and death among pre-dialysis patients: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Anemia during the predialysis period: A key to cardiac damage in renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES)

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Pathophysiology of cardiovascular damage in the early renal population.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Prevalence of cardiovascular damage in early renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

The beneficial effects of intervention in early renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Can physicians always explain the results of clinical trials? A case study of amlodipine in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Optimization of pre-ESRD care: the key to improved dialysis outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Early referral to the nephrologist and timely initiation of renal replacement therapy: a paradigm shift in the management of patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Prevalence of Hypertension in the US Adult Population : Results From the Third National Health and Nutrition Examination Survey, 1988-1991

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Glycemic control of older adults with type 2 diabetes: findings from the Third National Health and Nutrition Examination Survey, 1988-1994.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Physicians' practices in screening for the development of diabetic nephropathy and the use of glycosylated hemoglobin levels

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: important differences between practice and published guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Can we improve early mortality in patients receiving renal replacement therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Consequences of late referral on patient outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

An update on the referral pattern of patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Late referral of end-stage renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Delayed referral of black, Hispanic, and older patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Nonreferral and nonacceptance to dialysis by primary care physicians and nephrologists in Canada and the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

End-stage renal disease: factors affecting referral decisions by family physicians in Canada, the United States, and Britain

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Late diagnosis of chronic renal failure and mortality on maintenance dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Early referral and its impact on emergent first dialyses, health care costs, and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Timing of nephrology referral: influence on mortality and morbidity.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

The medical and economical advantages of early referral of chronic renal failure patients to renal specialists

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

An economic evaluation of early versus late referral of patients with progressive renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

The pattern of referral of patients with end-stage renal disease to the nephrologist--a European survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

When to initiate dialysis: effect of proposed US guidelines on survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Evaluation of DOQI guidelines: Early start of dialysis treatment is not associated with better health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Nephrologists as primary care providers: a review of the issues

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Nephrology nurse practitioners in a collaborative care model

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Multidisciplinary predialysis programs: quantification and limitations of their impact on patient outcomes in two Canadian settings

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Effects of multidisciplinary case management in patients with chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Applying disease management strategies to Medicare

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Timing of nephrologist referral and arteriovenous access use: the CHOICE Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Delayed nephrologist referral and inadequate vascular access in patients with advanced chronic kidney failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2803%2900188-4

7 January 2021

10.1016/S0272-6386(03)00188-4

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12722025